论文部分内容阅读
吉非替尼是表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKI),也是研究最为成熟的第1个非小细胞肺癌(non-small celllung cancer,NSCLC)靶向药物。目前,研究表明,EGFR-TKIs一线治疗EGFR突变的晚期NSLCLC患者中位无进展生存期(PFS)已达到9～10个月,总生存时间(OS)达2年以上;即使
Gefitinib is the first EGFR-TKI inhibitor and the first mature non-small cell lung cancer (NSCLC) targeted drug. At present, studies have shown that the median progression-free survival (PFS) of advanced NSCLC patients with EGFR mutations treated with EGFR-TKIs has reached 9 to 10 months and the overall survival time (OS) has reached more than 2 years; even though